Mouse CD30 Ligand/TNFSF8 APC‑conjugated Antibody

CD30 Ligand (CD30L)/TNFSF8 is a 39-40 kDa type II transmembrane glycoprotein that belongs to the TNF superfamily. CD30L is expressed on the cell surface of activated CD3⁺ CD4⁺ CD44⁺ T cells, and constitutively on mature CD11c⁺ CD40⁺ CD86⁺⁺ CCR7⁺ CD plus thymic medullary epithelium, CD4⁺ CD3^- CD11c^- OX40L⁺ splenic accessory cells, and IL-17 secreting V gamma 6 gamma delta T cells. Although the protein has also been described on granulocytes, B cells and monocytes, its presence on these cells in mouse is uncertain. The specific receptor for CD30L is CD30/TNFRSF8, a 90-100 kDa type I transmembrane glycoprotein that belongs to the TNF receptor superfamily. CD30 appears on virus-infected T and B cells and normal T and B cells after activation. Among T cells, CD30 is preferentially expressed on a subset of T cells producing Th2-type cytokines and on CD4⁺/CD8⁺ thymocytes that coexpress CD45RO and IL-4 receptor. CD30 ligation by CD30L mediates pleiotropic effects on CD30L-expression cells, including a reduction in IL-2 production and the promotion of IL-17A secretion. CD30 may act as a co‑stimulatory molecule in thymic negative selection, and may also play a critical role in the pathophysiology of Hodgkin's disease and other CD30⁺ lymphomas in human. Over aa 68-239, mouse CD30L shares 90% and 75% aa sequence identity with rat and human CD30L, respectively.